Drug profile · INN
gefapixant
LYFNUA
gefapixant (LYFNUA) is a p2x purinoceptor 3 antagonist.
EMA: approved Respiratory system (R05) R05DB29
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — gefapixant
- Class
- Respiratory system (R05)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
gefapixant (LYFNUA) is a p2x purinoceptor 3 antagonist.
Key facts
INN gefapixant
Brand LYFNUA
Mechanism P2X purinoceptor 3 antagonist
Target P2X purinoceptor 3
Therapeutic class Respiratory system (R05)
ATC code R05DB29
Mechanism of action
P2X purinoceptor 3 antagonist
Primary target: P2X purinoceptor 3
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is gefapixant?
gefapixant (LYFNUA) is a p2x purinoceptor 3 antagonist.
What is the brand name for gefapixant?
LYFNUA is a marketed brand name for gefapixant. Check FDA Drugs@FDA for the current US label holder and prescribing information.